Evidence map›Paper›PMID 34422015›Full record

ArticleFrontiers in genetics2021

Rare Genetic Disorders: Novel Treatment Strategies and Insights Into Human Biology.

Peter J Koch, Maranke I Koster

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Peter J KochDepartment of Anatomy and Cell Biology, Brody School of Medicine (BSOM) at East Carolina University (ECU), Greenville, NC, United States.
Maranke I KosterDepartment of Anatomy and Cell Biology, Brody School of Medicine (BSOM) at East Carolina University (ECU), Greenville, NC, United States.
East Carolina University · US

Funding

Mechanisms Underlying Tissue Fragility in Ectodermal DysplasiasR01AR072621 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI KOSTER, MARANKE I. · 2017 to 2022
$2.2M
Trp63 in limbal stem cell deficiencyR21EY029081 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOCH, PETER J., KOSTER, MARANKE I. · 2019 to 2020
$408k
NEI NIH HHS R21 EY029081NIAMS NIH HHS R01 AR072621
6 · The paper itself

Abstract

The last decade has seen a dramatic increase in innovative ideas for the treatment of genetic disorders for which no curative therapies exist. Gene and protein replacement therapies stand out as novel approaches to treat a select group of these diseases, such as certain tissue fragility disorders. Further, the advent of stem cell approaches, such as induced pluripotent stem cells (iPSC) technology, has led to the development of new methods of creating replacement tissues for regenerative medicine. This coincided with the discovery of genome editing techniques, which allow for the correction of disease-causing mutations. The culmination of these discoveries suggests that new and innovative therapies for monogenetic disorders affecting single organs or tissues are on the horizon. Challenges remain, however, especially with diseases that simultaneously affect several tissues and organs during development. Examples of this group of diseases include ectodermal dysplasias, genetic disorders affecting the development of tissues and organs such as the skin, cornea, and epithelial appendages. Gene or protein replacement strategies are unlikely to be successful in addressing the multiorgan phenotype of these diseases. Instead, we believe that a more effective approach will be to focus on correcting phenotypes in the most severely affected tissues. This could include the generation of replacement tissues or the identification of pharmaceutical compounds that correct disease pathways in specific tissues.

Indexed as

ectodermal dysplasiagene therapyiPSC disease modelingorphan (rare) diseasesprotein therapyrare genetic disordersTP63

Identifiers

PMID34422015
PMCPMC8378213
OpenAlexW3188969119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.